HIV Update 2018: A Front Row Seat

Slides:



Advertisements
Similar presentations
ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.
Advertisements

Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.
Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.
Switch to ATV + r-containing regimen - SWAN - SLOAT.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.
Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.
KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.
ID Week Review 2015 Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO October 2015.
Phase 3 Treatment Experienced
Novel Antiretroviral Studies and Strategies
Switch from TDF to TAF GS-US Study GS-US Study
Treatment-Naïve Adults
Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
Comparison of INSTI vs INSTI
Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Switch to PI/r + 3TC vs PI/r monotherapy
Upfront Combination Therapy vs Step-Up Approach for PAH:
Etravirine in Treatment Experienced DUET-2 (TMC125-C216)
Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109
Comparison of INSTI vs INSTI
ARV-trial.com Switch to D/C/F/TAF EMERALD Study 1.
ARV-trial.com Switch to LPV/r + RAL KITE Study 1.
Etravirine in Treatment Experienced DUET-1 (TMC125-C206)
Saquinavir + RTV versus Lopinavir-RTV in Treatment-Naïve GEMINI Trial
Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II
Switch to DTG + 3TC ASPIRE Study.
Dual Antiretroviral Therapy
ARV-trial.com Switch to E/C/F/TAF GS-US Study 1.
The Possibilities of PrEP: Introduction
Advances in HIV Care.
HIV Management: An Update on the Latest EACS Guidelines
Switch from TDF to TAF GS-US Study GS-US Study
Is Your Patient Engaged in Care
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Treating HIV Infection:
Switch to DTG-containing regimen
Translating Emerging HIV Data Into Clinical Practice
Switch to DRV/r + 3TC DUAL Study.
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Is it Time for a Paradigm Change in HIV Management?
HIV : New Agents, New Strategies
From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP
HIV Treatment: What Can You Do to Get and Keep Patients in Care?
Comparison of NRTI combinations
100 Partners PrEP[5] Efficacy 75% Adherence 81% 80
Comparison of PI vs PI ATV vs ATV/r BMS 089
Update From Seattle 2017.
Hepatitis C: After the Diagnosis
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Comparison of NNRTI vs PI/r
Comparison of NRTI combinations
Comparison of PI vs PI ATV vs ATV/r BMS 089
Comparison of NRTI combinations
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch to ATV- or ATV/r-containing regimen
Comparison of INSTI vs INSTI
Switch to LPV/r monotherapy
AMD Therapy: Where Are We Now and Where Are We Going?
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
Switch to DTG-containing regimen
Switch to ATV/r monotherapy
ARV-trial.com Switch to ATV/r + RAL HARNESS Study 1.
Comparison of PI vs PI ATV vs ATV/r BMS 089
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
DTG + 3TC vs DTG + TDF/FTC GEMINI.
Comparison of PI vs PI ATV vs ATV/r BMS 089
Characterizing Virological Suppression in Today's Treatment Paradigm
Presentation transcript:

HIV Update 2018: A Front Row Seat

Introduction

D/C/F/TAF Single-Tablet Regimen in Treatment-Naive Patients: AMBER

D/C/F/TAF Single-Tablet Regimen in Treatment-Naive Patients: AMBER Efficacy

D/C/F/TAF Single-Tablet Regimen in Treatment-Naive Patients: AMBER Safety

Bictegravir Coformulated With F/TAF in FDC vs DTG +F/TAF in Treatment-naive HIV-1-Positive Adults

Bictegravir Coformulated With F/TAF in FDC vs DTG +F/TAF in Treatment-Naive HIV-1-Positive Adults: Efficacy

Bictegravir Coformulated With F/TAF in FDC vs DTG +F/TAF in Treatment-Naive HIV-1-Positive Adults: Safety

DTG + 3TC vs DTG + TDF/FTC in Treatment-Naive Adults With HIV-1 Infection: GEMINI Efficacy Subgroup Analysis

DTG + 3TC vs DTG + TDF/FTC in Treatment-Naive Adults With HIV-1 Infection: GEMINI Subgroup Analysis of Discontinuations

DTG + 3TC vs DTG + TDF/FTC in Treatment-Naive Adults With HIV-1 Infection: GEMINI Safety Subgroup Analysis

Meta-Analysis Assessing Dual Therapy With PI/r + 3TC or PI/r + TDF

Meta-Analysis Assessing Dual Therapy With PI/r + 3TC or PI/r + TDF (Cont.)

Choosing a Dual Therapy Regimen

Selecting the Appropriate Patients for Dual Therapy Regimens

Comparable Viral Decay With DTG + 3TC vs DTG-Based Triple Therapy

Residual Viremia After Switch to DTG + 3TC

Ongoing Questions Regarding Dual Therapy

BMD in Virologically Suppressed Patients Aged ≥ 60 Years Switched From TDF- to TAF-Containing Regimens

Safety and Efficacy of Fostemsavir in Heavily Treatment-Experienced Patients: BRIGHTE

Safety and Efficacy of Fostemsavir in Heavily Treatment-Experienced Patients: BRIGHTE (Cont.)

Increases in Lipid Profile After Switch From TDF to TAF: Is It Clinically Relevant?

Increases in Lipid Profile After Switch From TDF to TAF: Is It Clinically Relevant? (Cont.)

Significant Weight Gain After Switch to DTG From a PI/r

Overview on Cure Research

STIs in Individuals Using PrEP

PrEP: In General and in Europe

Top 10 DDIs With ARVs

Top 10 DDIs With ARVs (Cont.)

Mental Health in PLWHIV

Program Conclusions

Program Conclusions (Cont.)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)